Literature DB >> 10679709

Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot.

C G Goetz1.   

Abstract

Amyotrophic lateral sclerosis is historically an important entity because its manifestations involve distinct signs that can be correlated with gray and white matter lesions at specific sites within the central nervous system. Working at the end of the nineteenth century, the celebrated neurologist, Jean-Martin Charcot, used this disorder as a prototypic example of the power of his research method, termed "méthode anatomoclinique." Using clinical cases and autopsy material, he showed how anatomical lesions in the nervous system could be accurately determined by the presence of carefully analyzed clinical signs. Charcot's work on amyotrophic lateral sclerosis brought together neurological entities formerly considered as disparate disorders, primary amyotrophy and primary lateral sclerosis. In addition, these studies contributed to the understanding of spinal cord and brain stem anatomy and the organization of the normal nervous system. Because of Charcot's fundamental contributions, the eponym "Charcot's disease" has been used internationally in association with amyotrophic lateral sclerosis. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10679709     DOI: 10.1002/(sici)1097-4598(200003)23:3<336::aid-mus4>3.0.co;2-l

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  22 in total

1.  Jean-Martin Charcot: the father of neurology.

Authors:  David R Kumar; Florence Aslinia; Steven H Yale; Joseph J Mazza
Journal:  Clin Med Res       Date:  2010-08-25

2.  [Jean-Martin Charcot in German neurology].

Authors:  H C Lehmann; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-02       Impact factor: 1.214

3.  Cataract surgery in a patient with amyotrophic lateral sclerosis: a case report.

Authors:  Maryo Cenk Kohen; Raciha Beril Kucumen
Journal:  Case Rep Ophthalmol       Date:  2011-06-28

4.  Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Michael Swash; George C Ebers
Journal:  Brain       Date:  2010-06-24       Impact factor: 13.501

Review 5.  The complex molecular biology of amyotrophic lateral sclerosis (ALS).

Authors:  Rachel L Redler; Nikolay V Dokholyan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 6.  Microglial TREM2 in amyotrophic lateral sclerosis.

Authors:  Manling Xie; Shunyi Zhao; Dale B Bosco; Aivi Nguyen; Long-Jun Wu
Journal:  Dev Neurobiol       Date:  2021-12-18       Impact factor: 3.964

Review 7.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

Review 8.  DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity.

Authors:  Jannigje Rachel Kok; Nelma M Palminha; Cleide Dos Santos Souza; Sherif F El-Khamisy; Laura Ferraiuolo
Journal:  Cell Mol Life Sci       Date:  2021-06-26       Impact factor: 9.261

9.  Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.

Authors:  Carol Milligan; Nazem Atassi; Suma Babu; Richard J Barohn; James B Caress; Merit E Cudkowicz; Armineuza Evora; Gregory A Hawkins; Marlena Wosiski-Kuhn; Eric A Macklin; Jeremy M Shefner; Zachary Simmons; Robert P Bowser; Shafeeq S Ladha
Journal:  Muscle Nerve       Date:  2021-06-24       Impact factor: 3.852

Review 10.  Biomedical signals and machine learning in amyotrophic lateral sclerosis: a systematic review.

Authors:  Felipe Fernandes; Ingridy Barbalho; Daniele Barros; Ricardo Valentim; César Teixeira; Jorge Henriques; Paulo Gil; Mário Dourado Júnior
Journal:  Biomed Eng Online       Date:  2021-06-15       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.